Dermata Therapeutics, Inc. (DRMA) Form 8-K — May 13, 2026
Dermata Therapeutics, Inc. (DRMA) reported financial results for the first quarter of 2026, with a net loss of $1.847 million and a cash position of $6.945 million. The company also announced the launch of its new skincare brand, Tome, and the hiring of Kyra Peckaitis as Vice President of Marketing. Dermata raised $2.0 million in net proceeds from its at-the-market (ATM) financing facility in Q1 2026, which will help fund operations into the first quarter of 2027.
Key figures
- Eps
- -0.48
- Eps Beat
- 0
- Revenue
- 0
- Guidance
- The Company expects its current cash resources to be sufficient to fund operations into the first quarter of 2027.
- Net Income
- -1,847
- Total Debt
- 1,052
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 7,465
- Cash Position
- 6,945
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 2,000
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 3,858,921
- Cash Used In Operations
- 2,500
- Research And Development Expenses
- 384
- Selling General And Administrative Expenses
- 1,542
Price after filing
1 day: +3.4%7 days: +5.0%30 days: +2.5%
Close on the filing date to close N calendar days later (from $1.19). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.